• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Pediatr . Effectiveness of BNT162b2 Vaccination During Pregnancy in Preventing Hospitalization for SARS-CoV-2 in Infants

tetano

Editor, Senior Moderator
J Pediatr


. 2022 Oct 14;S0022-3476(22)00896-4.
doi: 10.1016/j.jpeds.2022.09.059. Online ahead of print.
Effectiveness of BNT162b2 Vaccination During Pregnancy in Preventing Hospitalization for SARS-CoV-2 in Infants


Dana Danino[SUP] 1 [/SUP], Liat Ashkenazi-Hoffnung[SUP] 2 [/SUP], Alejandro Diaz[SUP] 3 [/SUP], Amir Dov Erps[SUP] 4 [/SUP], Noa Eliakim-Raz[SUP] 5 [/SUP], Yonat Shemer Avni[SUP] 6 [/SUP], David Greenberg[SUP] 7 [/SUP], Noga Givon-Lavi[SUP] 7 [/SUP], Ilan Youngster[SUP] 8 [/SUP]



Affiliations

Abstract

Objective: To Assessthe clinical effectiveness of the BNT162b2 vaccine during pregnancy in preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) hospitalizations of infants.
Study design: A retrospective, multicenter, 1:3 case-control (test-negative) study. Symptomatic hospitalized infants <6 months, with positive SARS-CoV-2 polymerase chain reaction (PCR) test between 1/3/2021-31/11/2021 were matched by age and time to negative controls, hospitalized with symptoms compatible with SARS-CoV-2 infection. Mothers were defined as fully vaccinated; received 2 doses of BNT162b2 with the second given 2 weeks to 6 months before delivery, or partially vaccinated; received only one dose or 2 doses with the second given >6 months or <2 weeks before delivery. Severe SARS-CoV-2 was defined as need for assisted ventilation.
Results: 116 SARS-CoV-2 positive infants were matched to 348 negative controls with symptoms compatible with SARS-CoV-2 infection. The effectiveness of fully vaccinated mothers was 61.6% (CI: 31.9-78.4) and the effectiveness of partially vaccinated mothers was not significant. Effectiveness was higher in infants 0-2 vs. 3-6 months of age. The effectiveness (57.1%, CI: 22.8-76.4) was similar when excluding mothers who were infected with SARS-CoV-2 during pregnancy. OR of severe infection in infants born to unvaccinated versus fully vaccinated mothers was 5.8.
Conclusions: At least 2 doses of BNT162b2 vaccine administered during the second or third trimester of pregnancy had an effectiveness of 61.6% in reduction of hospitalization for SARS-CoV-2 infection in infants <6 months.

Keywords: Maternal vaccination; SARS-CoV-2; infants’ hospitalizations; pregnancy.
 
Back
Top Bottom